PRESS RELEASE

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with…Read More

You might also be interested in reading Terraform Labs’ bankruptcy estate targets Jump Trading in $4B lawsuit.